Clinical trial · Interventional
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA: a Prospective Cohort Study
NCT05375370CI-TRIAL-00102648REMNANTrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| circulating tumor DNA dosage | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patient with hepatocellular carcinoma
- description
- Circulating tumor DNA dosage will be done to patients with hepatocellular carcinoma
- interventionNames
- Other: circulating tumor DNA dosage
Primary outcomes (2)
- measure
- Change in tcNA dosage between baseline and 6 Months
- timeFrame
- 6 months
- description
- evolution of tcDNA percentage between Baseline and at 6 months after surgery
- measure
- Change in tcDNA dosage between baseline and 3 Months
- timeFrame
- 3 months
- description
- evolution of tcDNA percentage between Baseline and at 3 months after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years 2. HCC diagnosed on consensus radiological criteria in cirrhotic patients (EASL-EORTC 2012): helical CT or MRI with triple arterial, portal and late acquisition. The diagnosis is based on the presence of hypervascularization at the early arterial time (wash-in) with wash-out (hypodensity or hypointensity compared to non-tumor liver parenchyma) at the portal phase or late phase compared to non-tumor parenchyma. 3. HCC diagnosed histologically in the absence of a diagnosis on imaging (see IC n°2 above) 4. Patient operated on for liver resection or radiofrequency destruction 5. Treatment decision validated by the digestive oncology PCR 6. Patient having read and understood the information letter and signed the non-opposition form 7. Patient follow-up at the Charles Nicolle University Hospital in Rouen Exclusion Criteria: 1. Other active cancer or hematological malignancy 2. Contra-indication to surgery 3. Patient not affiliated to the social security system 4. Pregnant woman or parturient or breastfeeding 5. Person under court protection, sub guardianship or curatorship
References
Publications (0)
Data not yet available
No reference posted for this study.